Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Jairo Cajamarca-Baron, Jhon Buitrago-Bohorquez, Jose Emmanuel Mendoza Orozco, Omar Segura, Diana Guavita-Navarro, Laura Gallego-Cardona, Hector Cubides, Ana Maria Arredondo, Alejandro Escobar, Adriana Rojas-Villarraga
Summary: This systematic review evaluates the role of intravenous immunoglobulin (IVIg) in the care of patients with lupus nephritis (LN). The results suggest that IVIg therapy is effective for LN patients refractory to conventional treatment, but caution is needed when using it on patients with class V LN. Although adverse reactions are few, these data should be interpreted cautiously due to the lack of controlled studies with long-term follow-up.
AUTOIMMUNITY REVIEWS
(2022)
Review
Immunology
Zhihui Liu, Ruijuan Cheng, Yi Liu
Summary: This study evaluated the safety of anifrolumab in patients with moderate to severe systemic lupus erythematosus (SLE). The results showed that serious adverse events were less common in the anifrolumab group compared to the placebo group. The most common adverse events included upper respiratory tract infection, nasopharyngitis, bronchitis, and herpes zoster. Anifrolumab is considered a well-tolerated option for the treatment of SLE patients with good safety.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Qian Wu, Yang Liu, Wei Wang, Yu Zhang, Kui Liu, Song-Hua Chen, Bin Chen
Summary: This meta-analysis investigates the incidence and prevalence of tuberculosis (TB) in patients with systemic lupus erythematosus (SLE). The results show that both the incidence and prevalence of TB are high among SLE patients. Subgroup analyses also reveal that the incidence is higher in Africa and countries with a high TB burden, while the prevalence is elevated in Asia, patients taking a high daily dose of glucocorticoids, studies with small sample sizes and those conducted before 2001.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Obstetrics & Gynecology
Joao Pedro Ferrari-Souza, Mirela Tschiedel Pedrotti, Enrico Emerim Moretto, Laura Penso Farenzena, Luis Guilherme Crippa, Joao Sabino Cunha-Filho
Summary: This study found an association between endometriosis and systemic lupus erythematosus (SLE) through a systematic review and meta-analysis. Although the included studies had limited quality, the results suggest a link between endometriosis and SLE.
REPRODUCTIVE SCIENCES
(2023)
Review
Dentistry, Oral Surgery & Medicine
Syed Basit Hussain, Yago Leira, Syeda Ambreen Zehra, Joao Botelho, Vanessa Machado, Coziana Ciurtin, Francesco D'Aiuto, Marco Orlandi
Summary: This systematic review and meta-analysis revealed a significant association between systemic lupus erythematosus (SLE) and periodontitis (PD), suggesting that patients with SLE have a higher risk of developing PD. Further investigation is needed to explore the relationship between PD and SLE.
JOURNAL OF PERIODONTAL RESEARCH
(2022)
Review
Immunology
Xiaohong Lu, YanHua Wang, Jing Zhang, Dan Pu, Nan Hu, Jing Luo, Qi An, Lan He
Summary: The systematic review and meta-analysis found that patients with systemic lupus erythematosus (SLE) have a higher risk of developing cardiovascular disease (CVD) compared to the general or healthy population, and the risk of CVD in lupus nephritis (LN) patients is significantly higher than in SLE patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Health Care Sciences & Services
Daniel A. Rossignol, Richard E. Frye
Summary: IVIG treatment may be associated with improvements in ASD symptoms, including communication, irritability, hyperactivity, and cognition. However, there is significant variability among studies, and many are limited by the lack of standardized objective outcome measures. Further research is needed to determine the subset of children with ASD who may best respond to this treatment and to investigate potential biomarkers for identifying responsive candidates.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Orthopedics
Yiwei Huang, Danni Guan, Yijin Li, Jiahao Li, Yirong Zeng
Summary: This study reviewed the current evidence on complications and postoperative function in systemic lupus erythematosus (SLE) patients undergoing total hip arthroplasty (THA). The meta-analysis results showed that SLE patients have an increased risk of deep vein thrombosis, wound infection, dislocation, periprosthetic fracture, and revision after THA compared to non-SLE patients.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
(2022)
Review
Immunology
S. Giambalvo, C. Garaffoni, E. Silvagni, F. Furini, R. Rizzo, M. Govoni, A. Bortoluzzi
Summary: This systematic literature review aimed to explore the factors associated with fertility outcomes in women of childbearing age with systemic lupus erythematosus (SLE). The study found that exposure to cyclophosphamide and its cumulative dose can impair gonadal function in SLE women, leading to amenorrhea and premature ovarian failure (POF). Certain treatments were associated with a lower risk of POF. Hormonal and serological factors did not appear to impact fertility outcomes, but could be used as surrogate markers of fertility.
AUTOIMMUNITY REVIEWS
(2022)
Review
Medicine, Research & Experimental
Hamidreza Ebrahimiyan, Shayan Mostafaei, Saeed Aslani, Seyedeh Tahereh Faezi, Elham Farhadi, Ahmadreza Jamshidi, Mahdi Mahmoudi
Summary: In this study, a meta-analysis was performed to investigate the association between ITGAM gene rs1143679 SNP and MBL gene rs1800451 SNP with SLE risk. The results showed a significant positive association between rs1143679 and SLE risk, while rs1800451 was significantly associated with decreased susceptibility to SLE.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Review
Immunology
Wan-tong Zhang, Zhao Liu, Bao-chen Zhu, Zi-yang Cui, Cheng Huang, Xu-jie Wang, Fang Lu, Qiu-yan Li, Wei-liang Weng, Guo-dong Hua, Chun-miao Xue
Summary: Current smokers with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease (CVD).
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Ya Lan Chen, Jie Meng, Cong Li
Summary: Intestinal perforation is a rare complication of systemic lupus erythematosus (SLE). This study retrospectively collected and analyzed the clinical data of 18 cases of SLE-related intestinal perforation. The results suggest that risk factors for intestinal perforation in SLE include disease duration of >5 years, SLE disease activity index score of >10, nonstandard use of steroids, and concomitant presence of other immune system diseases. Early diagnosis, aggressive resuscitation, antibiotics, steroid therapy, and prompt surgical intervention are key to successfully managing such cases.
Review
Pharmacology & Pharmacy
Xiaobo Li, Zhouqing He, Li Ru, Yueming Yuan, Zheng Yuan, Pengfei Chen, Zhiyong Xu, Qi Wang, Jianping Song, Qin Xu
Summary: The combination of Qinghao Biejia decoction with conventional chemical medicine shows advantages in treating SLE by improving overall response rate, reducing disease activity index and symptom scores, enhancing immunological indexes, and decreasing adverse events. However, more high-quality RCTs are needed to confirm these findings.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Xian-Bao Li, Nv-Wei Cao, Xiu-Jie Chu, Hao-Yue Zhou, Hua Wang, Si-Jie Yu, Dong-Qing Ye, Bao-Zhu Li
Summary: Antimalarials, especially hydroxychloroquine, may reduce the risk of cancer in patients with systemic lupus erythematosus (SLE), with significant risk reduction seen in Asian populations and SLE patients from multiple centers.
ANNALS OF MEDICINE
(2021)